The Only Chikungunya Vaccine Just Got Pulled. Now What?

The financial toll has been significant. Valneva posted a net loss of €115.2 million in 2025, compared to just €12.2 million the year before (though 2024 was flatted by a one-time €90.8 million gain from selling IXCHIQ's Priority Review Voucher). In Q1 2026, IXCHIQ contributed a mere €1.6 million in sales, and the company slashed its full-year revenue guidance, trimming product sales expectations to €135–150 million from an earlier €145–160 million range.

Valneva is now restructuring, targeting a 25–35% cut in total operating expenses and pinning its survival hopes on a Lyme disease vaccine being developed with Pfizer.

The Disease Isn't Going Anywhere

Chikungunya might sound exotic, but it's becoming less so by the year. The virus, spread by Aedes mosquitoes, causes debilitating joint pain that can last months. In 2025 alone, the Americas reported over 315,000 cases and 171 deaths.

In the U.S., imported cases more than doubled from 199 in 2024 to 466 in 2025. And for the first time since 2019, a locally acquired case turned up in downstate New York, where the Aedes albopictus mosquito has established a foothold. That's not Florida or Texas; that's the tristate area.

Climate change is widening the welcome mat. Warmer temperatures extend the mosquito season and push vector habitats northward. The risk envelope for chikungunya in the U.S. is expanding, even as the only approved countermeasure has been pulled off the shelf.

The Neglected Disease Trap

IXCHIQ's collapse exposes a deeper problem that haunts the entire category of neglected tropical disease vaccines. The economics are brutal: the people who need these vaccines most are overwhelmingly poor, global procurement prices hover around $2–3 per dose, and U.S. demand is limited to travelers and military personnel.

In the American market, commercial success hinges on ACIP (the Advisory Committee on Immunization Practices), whose recommendations essentially determine whether insurers will cover a vaccine. A narrow, risk-based recommendation ("consider for certain travelers") translates to tiny volumes. Without broad ACIP support, federal procurement, or stockpile contracts, the math simply doesn't work.

That's not a market failure you can optimize your way out of. It's a structural impossibility without public funding, philanthropic backing, or advance purchase commitments.

Is Anyone Else Stepping Up?

The good news: IXCHIQ wasn't the only horse in this race, just the first across the finish line.

Bavarian Nordic's Vimkunya, a virus-like particle (VLP) vaccine, is now the second licensed chikungunya vaccine globally. Unlike IXCHIQ, it uses a non-replicating platform, which sidesteps the "vaccine causes the disease" problem entirely. It could become the default option for travelers and at-risk populations.

Behind it, Bharat Biotech and the International Vaccine Institute are running Phase 2/3 trials of an inactivated vaccine (BBV87) across Colombia, Panama, Thailand, Guatemala, and Costa Rica, with India likely to be the first country to license it. Moderna has an mRNA candidate (mRNA-1388) in Phase 1 that showed 100% seroconversion at the highest dose, and Oxford is developing an adenoviral vector approach similar to the platform behind its COVID vaccine.

So the pipeline exists. But "exists" and "available" are very different things, especially for endemic countries that lack regulatory pathways, financing mechanisms, and delivery infrastructure.

The Uncomfortable Bottom Line

Valneva's chikungunya story is a cautionary tale wrapped in a public health gap. A genuinely needed vaccine made it all the way to market, only to be undone by the very biology it was designed to fight. The live virus was too hot; the commercial market was too cold.

What's left is a disease that's spreading, a pipeline that's years from filling the gap in the U.S., and a reminder that "approved" doesn't mean "safe" and "needed" doesn't mean "profitable." Bavarian Nordic's VLP vaccine offers the best near-term hope, but until chikungunya preparedness gets the kind of funding and political attention reserved for pandemic threats, we're essentially watching a slow-motion problem with no fire extinguisher in sight.